AbbVie looks to shed Allergan's legacy women's health unit as it hunkers down for Humira biosim doomsday — report
With the clock ticking on its blockbuster Humira patent in the US, AbbVie is reportedly in talks to sell the $5 billion women’s health portfolio it acquired from Allergan in order to pay off debt and focus on new areas.
Unnamed sources told Reuters that AbbVie is working with Morgan Stanley to auction off the portfolio, which includes the Lo Loestrin Fe birth control pill. The potential sale has reportedly attracted the likes of CVC Capital Partners, which the sources say is eyeing the unit for its portfolio company, Theramex.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.